Short answer
Aurinia Pharmaceuticals Inc. (AUPH) filed an 8-K current report with the SEC on October 30, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Aurinia announced financial results for the three months ended September 30, 2026.
Aurinia Pharmaceuticals Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Aurinia announced financial results for the three months ended September 30, 2026
- Exhibit 99.1 contains the detailed quarterly financial results for investor review
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $83.7M, up 14%; nine-month revenue $244.6M, up 19%, led by LUPKYNIS sales
- Nine-month net income $103.5M, up 35%, with operating cash flow $131.5M, up 46%
- 2026 revenue guidance raised to $325M-$330M; product-sales guidance narrowed to $310M-$315M
- Cash, restricted cash and investments reached $486.9M; 5.0M shares repurchased for $74.9M
- PRESERVE Phase 4 study targets approximately 150 patients, expanding LUPKYNIS combination-treatment evidence in lupus nephritis
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aurinia Pharmaceuticals Inc. 8-K filings
Get the next AUPH 8-K as it lands
Follow AUPH for push alerts, or ask the research agent what this filing means.